- Home
- BATL vs NCEL Comparison
BATL vs NCEL Comparison
Compare BATL & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BATL | NCEL |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1M | 20.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BATL | NCEL |
|---|---|---|
| Price | $1.19 | $3.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 78.2K | ★ 78.9K |
| Earning Date | 11-13-2025 | 12-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $183,422,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $2.91 |
| 52 Week High | $3.67 | $7.64 |
Technical Indicators
Market Signals| Indicator | BATL | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | N/A |
| Support Level | $1.15 | N/A |
| Resistance Level | $1.25 | N/A |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 27.60 | 0.00 |
Price Performance
Historical ComparisonAbout BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.